147 related articles for article (PubMed ID: 21391913)
1. Network perspectives on HDM2 inhibitor chemotherapy combinations.
Azmi AS; Beck FW; Sarkar FH; Mohammad RM
Curr Pharm Des; 2011; 17(6):640-52. PubMed ID: 21391913
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
Patel S; Player MR
Expert Opin Investig Drugs; 2008 Dec; 17(12):1865-82. PubMed ID: 19012502
[TBL] [Abstract][Full Text] [Related]
3. Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors.
Azmi AS; Banerjee S; Ali S; Wang Z; Bao B; Beck FW; Maitah M; Choi M; Shields TF; Philip PA; Sarkar FH; Mohammad RM
Oncotarget; 2011 May; 2(5):378-92. PubMed ID: 21623005
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the therapeutic perspectives of Nutlin-3.
Secchiero P; Bosco R; Celeghini C; Zauli G
Curr Pharm Des; 2011; 17(6):569-77. PubMed ID: 21391907
[TBL] [Abstract][Full Text] [Related]
5. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo.
Koblish HK; Zhao S; Franks CF; Donatelli RR; Tominovich RM; LaFrance LV; Leonard KA; Gushue JM; Parks DJ; Calvo RR; Milkiewicz KL; Marugán JJ; Raboisson P; Cummings MD; Grasberger BL; Johnson DL; Lu T; Molloy CJ; Maroney AC
Mol Cancer Ther; 2006 Jan; 5(1):160-9. PubMed ID: 16432175
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update.
Millard M; Pathania D; Grande F; Xu S; Neamati N
Curr Pharm Des; 2011; 17(6):536-59. PubMed ID: 21391905
[TBL] [Abstract][Full Text] [Related]
7. Small molecule protein-protein inhibitors for the p53-MDM2 interaction.
Dudkina AS; Lindsley CW
Curr Top Med Chem; 2007; 7(10):952-60. PubMed ID: 17508926
[TBL] [Abstract][Full Text] [Related]
8. Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides.
Wei SJ; Chee S; Yurlova L; Lane D; Verma C; Brown C; Ghadessy F
Oncotarget; 2016 May; 7(22):32232-46. PubMed ID: 27057630
[TBL] [Abstract][Full Text] [Related]
9. Peptide activators of the p53 tumor suppressor.
Zhan C; Lu W
Curr Pharm Des; 2011; 17(6):603-9. PubMed ID: 21391910
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical reactivation of p53 pathways in cancer.
Azmi AS
Curr Pharm Des; 2011; 17(6):534-5. PubMed ID: 21391903
[No Abstract] [Full Text] [Related]
11. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.
Chène P; Fuchs J; Bohn J; García-Echeverría C; Furet P; Fabbro D
J Mol Biol; 2000 May; 299(1):245-53. PubMed ID: 10860736
[TBL] [Abstract][Full Text] [Related]
12. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
Gupta A; Shah K; Oza MJ; Behl T
Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
[TBL] [Abstract][Full Text] [Related]
13. The role of p53 in cancer drug resistance and targeted chemotherapy.
Hientz K; Mohr A; Bhakta-Guha D; Efferth T
Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the p53/hDM2 protein-protein interaction by cyclometallated iridium(III) compounds.
Liu LJ; He B; Miles JA; Wang W; Mao Z; Che WI; Lu JJ; Chen XP; Wilson AJ; Ma DL; Leung CH
Oncotarget; 2016 Mar; 7(12):13965-75. PubMed ID: 26883110
[TBL] [Abstract][Full Text] [Related]
15. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.
Patton JT; Mayo LD; Singhi AD; Gudkov AV; Stark GR; Jackson MW
Cancer Res; 2006 Mar; 66(6):3169-76. PubMed ID: 16540668
[TBL] [Abstract][Full Text] [Related]
16. Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents.
Mondal C; Halder AK; Adhikari N; Saha A; Saha KD; Gayen S; Jha T
Eur J Med Chem; 2015 Jan; 90():860-75. PubMed ID: 25535952
[TBL] [Abstract][Full Text] [Related]
17. A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.
Jeay S; Gaulis S; Ferretti S; Bitter H; Ito M; Valat T; Murakami M; Ruetz S; Guthy DA; Rynn C; Jensen MR; Wiesmann M; Kallen J; Furet P; Gessier F; Holzer P; Masuya K; Würthner J; Halilovic E; Hofmann F; Sellers WR; Graus Porta D
Elife; 2015 May; 4():. PubMed ID: 25965177
[TBL] [Abstract][Full Text] [Related]
18. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
Phelps M; Darley M; Primrose JN; Blaydes JP
Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
[TBL] [Abstract][Full Text] [Related]
19. [Abnormal p53-HDM2 interaction in hematological malignancy].
Tabe Y; Kojima K
Nihon Rinsho; 2014 Jun; 72(6):1042-6. PubMed ID: 25016801
[TBL] [Abstract][Full Text] [Related]
20. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
Lau LM; Nugent JK; Zhao X; Irwin MS
Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
